Psyence Biomedical (PBM) has released an update.
Psyence Biomedical Ltd. has entered into a stock purchase agreement with White Lion Capital, LLC, allowing for the sale of up to $25 million in common stock. This agreement is based on exemptions from registration requirements, and the company is concurrently establishing a Registration Rights Agreement to facilitate the resale of these securities. The deal, effective from July 25, 2024, will enable White Lion Capital to purchase shares over a two-year period or until the full commitment amount is reached.
For further insights into PBM stock, check out TipRanks’ Stock Analysis page.
